Protection of Mice Against Pandemic H1N1 Influenza Virus Challenge After Immunization with Baculovirus-Expressed Stabilizing Peptide Fusion Hemagglutinin Protein

• Published in: Journal of microbiology and biotechnology Vol. 25; no. 2; pp. 280 - 287
• Main Authors: Yang, Eunji, Cho, Yonggeun, Choi, Jung-ah, Choi, YoungJoo, Park, Pil-Gu, Park, Eunsun, Lee, Choong Hwan, Lee, Hyeja, Kim, Jongsun, Lee, Jae Myun, Song, Manki
• Format: Journal Article
• Language: English
• Published: 한국미생물·생명공학회 28.02.2015
• Subjects: 생물학
• ISSN: 1017-7825; 1738-8872
• DOI: 10.4014/jmb.1410.10035

Current influenza vaccines are produced in embryonated chicken eggs. However, egg-based vaccines have various problems. To address these problems, recombinant protein vaccines have been developed as new vaccine candidates. Unfortunately, recombinant proteins frequently encounter aggregation and low stability during their biogenesis. It has been previously demonstrated that recombinantly expressed proteins can be greatly stabilized with high solubility by fusing stabilizing peptide (SP) derived from the C-terminal acidic tail of human synuclein (ATS). To investigate whether SP fusion proteins can induce protective immunity in mice, we produced influenza HA and SP fusion protein using a baculovirus expression system. In in vitro tests, SP-fused recombinant HA1 (SP-rHA1) was shown to be more stable than recombinant HA1 (rHA1). Mice were immunized intramuscularly with baculovirus-expressed rHA1 protein or SP-rHA1 protein (2 μg/mouse) formulated with aluminum hydroxide. Antibody responses were determined by ELISA and hemagglutination inhibition assay. We observed that SP-rHA1 immunization elicited HA-specific antibody responses that were comparable to rHA1 immunization. These results indicate that fusion of SP to rHA1 does not negatively affect the immunogenicity of the vaccine candidate. Therefore, it is possible to apply SP fusion technology to develop stable recombinant protein vaccines with high solubility. KCI Citation Count: 0